Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S. regulators ordering an end to the practice.

The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Novo Nordisk, the maker of Wegovy, will focus on commercial strategy and cost reduction. This decision follows a profit ...